ROSG: Rosetta Genomics Ltd. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 21, 2:31 PM Shares of Rosetta Genomics (ROSG +2.4%) recovered from early losses to trade back near the prior day's highs after the company announced yesterday that it had signed a credentialing agreement with PPO provider Prime Health Services under which ROSG's miRview mets2 test will be included in Prime's covered products and services. Comment! [Healthcare, On the Move]
Monday, May 20, 9:26 AM Rosetta Genomics (ROSG) jumps 11.76% before the bell after executing a credentialing agreement with managed care company Prime Health Services under which the company's miRview mets2 test "will be included in Prime's covered products and services." The agreement is ROSG's first with a U.S. PPO. (PR) Comment! [On the Move]
Monday, May 20, 9:10 AM Premarket gainers: AQ +116%. MEAD +97%. PACT +38%. WBSN +28%. RSOL +26%. ROSG +16%. JASO +16%. JRCC +14%. QIHU +12%. LDK +9%. PXP +7%. IQNT +5%. VOYA +5%. DANG +5%.
Losers: XNPT -26%. NBG -8%. Comment! [On the Move]
Wednesday, May 15, 3:22 PM Gene-related stocks are getting a big bump today on the back of Angelina Jolie's recent decision to have a mastectomy to prevent possible breast cancer: Rosetta Genomics (ROSG +15.5%), Genetic Technologies (GENE +12.9%), Diagnocure (DGCRF.PK +12%), GeneNews (GNSWF.PK +5%). Myriad Genetics (MYGN -2.2%) is lower on a bout of profit-taking, possibly exacerbated by news of some insider selling today by its CEO as well. Comment! [Healthcare, On the Move]
Friday, May 10, 9:49 AM Rosetta Genomics (ROSG +0.6%) rises after saying it has received a $665K negotiated settlement payment from Sanra Labs in connection with ROSG's sale of Parkway Clinical Laboratories. (PR) Comment! [Healthcare, On the Move]
Thursday, April 18, 10:57 AM Rosetta Genomics (ROSG) drifts back to unchanged following a 5% pop in the pre-market after it announced a settlement agreement with Sanra Laboratories on the previous sale of Parkway Clinical Laboratories. Under the terms of the settlement, Sanra agrees to make a "best effort" to pay ROSG $625K, in addition to all sums previously paid by them according to the stock purchase agreement entered into in May 2009. Comment! [Healthcare]
Friday, April 12, 11:37 AM Rosetta Genomics (ROSG -3.6%) slips after Sidoti cut the shares to Neutral earlier today. The stock has essentially been dead money since last November, trading in a narrow range between $4 - $5 after cratering off a $23 higher earlier in the year. Just yesterday, Aegis cut its price target on the stock as well. On the surface, that may not seem too significant, but it's worth noting that Aegis has acted as the placement agent for the last four of ROSG’s public offerings. 1 Comment [Healthcare, On the Move]
Monday, April 1, 1:46 PM Rosetta Genomics (ROSG +4.8%) gets a lift today after saying earlier that a manuscript on the development and validation of the Company's microRNA-based diagnostic assay for the classification of renal cell tumors has been accepted for publication by Molecular Oncology. Comment! [Healthcare, On the Move]
Thursday, February 14, 9:10 AM Premarket gainers: ART +33%. ANGI +30%. STZ +29%. HNZ +20%. SKX +10%. ROSG +7%. Z +8%. ANR +7%. BUD +5%. EQIX +5%.
Losers: AFFY -22%. NSPH -20%. WTW -17%. CTL -17%. TRIP -10%. ULTA -9%. WFM -7%. BBRY -5%. ARR -6%. WIN -5%. 1 Comment [On the Move]
Thursday, February 14, 9:03 AM Rosetta Genomics (ROSG +8.8%) climbs smartly after receiving two notices of allowance for patent applications for its microRNA technology. One of the patents is used in Rosetta's miRview product for helping to identify the tumor of origin in cancer and the other is related to herpes. (PR) Comment! [Healthcare, On the Move]
Wednesday, January 9, 12:45 PM Midday top 10 gainers: ININ +19%. KGJI +15%. SINO +14%. ZIPR +14%. CTC +14%. ROSG +13%. CSIQ +13%. TSL +13%. SAAS +12%. SMED +12%.
Midday top 10 Losers: SCHS -29%. PPHM -12%. PTEK -11%. CTIC -11%. DLGC -11%. MG -11%. ZA -10%. DYSL -9%. APOL -9%. CRK -8%. Comment! [On the Move]
Wednesday, January 9, 9:38 AM Rosetta Genomics (ROSG) soars 19% after saying that its miRview mets2 cancer diagnostic test performed well in a study. miRview mets2 is able to identify the primary sites of secondary cancer tumors that routine testing is unable to. (PR) Comment! [Healthcare, On the Move]
Wednesday, January 9, 9:10 AM Premarket gainers: ROSG +18%. NUVA +14%. GPN +8%. CLWR +7%. SKUL +7%.
Losers: APOL -8%. XTEX -6%. MT -5%.
Comment! [On the Move]
Friday, November 23, 2012, 12:45 PM Midday top 10 gainers: CCCL +42%. MAPP +21%. BGMD +21%. MCP +18%. INUV +16%. FIZZ +15%. ROSG +14%. DAC +13%. RIMM +13%. RIC +12%.
Top 10 Losers: KITD -64%. PTGI -17%. SGOC -12%. HDSN -9%. TELK -9%. SAB -8%. HRT -8%. NFEC -8%. THQI -7%. RCON -7%. 1 Comment [On the Move]
Friday, November 23, 2012, 10:23 AM Rosetta Genomics (ROSG +9.7%) spikes as New York grants final approval for its miRview lung assay that can accurately differentiate between the four main subtypes of lung cancer using small amounts of tumor cells. With this approval, ROSG can continue to offer miRviev in all 50 U.S. states; NY is the only state that requires an independent regulatory review process for lab-developed tests. 1 Comment [Healthcare, On the Move]
Tuesday, November 6, 2012, 12:45 PM Midday top 10 gainers: NVGN +89%. FN +25%. ENOC +19%. ROSG +19%. WTW +18%. CSC +17%. ODP +17%. JIVE +16%. AOL +16%. ACAD +15%. Midday top 10 Losers: THQI -48%. SREV -37%. SYPR -35%. MKTG -30%. VVUS -23%. CDE -22%. CBM -22%. Z -19%. MMYT -18%. ANTH -17%. Comment!

ROSG Rosetta Genomics Ltd.

ROSG

Rosetta Genomics Ltd.